AD HOC ANNOUNCEMENT Marinomed Biotech AG announces top line results of the Phase III study for Budesolv
Vienna, Tuesday, April 23, 2019.Marinomed Biotech AG, a globally active biopharmaceutical company with headquarters in Vienna, has announced the successful…
Weiterlesen